$9.39 -0.24 (-2.49%)
11/27/2009 1:00 PM

Seattle Genetics, Inc. (SGEN)

CAPS Rating: 4 out of 5

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Featured Broker Partners